Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer

Abstract

The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by NTRK genes and have a role in the development and normal functioning of the nervous system. Since the discovery of an oncogenic NTRK gene fusion in colorectal cancer in 1986, over 80 different fusion partner genes have been identified in a wide array of adult and paediatric tumours, providing actionable targets for targeted therapy. This review describes the normal function and physiology of TRK receptors and the biology behind NTRK gene fusions and how they act as oncogenic drivers in cancer. Finally, an overview of the incidence and prevalence of NTRK gene fusions in various types of cancers is discussed.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 120

1. 1.

   Schram AM, Chang MT, Jonsson P et al Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol2017; 14(12): 735–748.

   Not in our library10.1038/nrclinonc.2017.127

2. 2.

   Weier HU, Rhein AP, Shadravan F et al Rapid physical mapping of the human trk protooncogene (NTRK1) to human chromosome 1q21-q22 by P1 clone selection, fluorescence in situ hybridization (FISH), and computer-assisted microscopy. Genomics1995; 26(2): 390–393.

   Not in our library10.1016/0888-7543(95)80226-c

3. 3.

   Nakagawara A, Liu XG, Ikegaki N et al Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics1995; 25(2): 538–546.

   Not in our library10.1016/0888-7543(95)80055-q

4. 4.

   Valent A, Danglot G, Bernheim A. Mapping of the tyrosine kinase receptors trkA (NTRK1), trkB (NTRK2) and trkC(NTRK3) to human chromosomes 1q22, 9q22 and 15q25 by fluorescence in situ hybridization. Eur J Hum Genet1997; 5(2): 102–104.

   Not in our library

5. 5.

   Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Discord Drug Targets2008; 7(1): 46–62.

   Not in our library10.2174/187152708783885174

6. 6.

   Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol2018; 15(12): 731–747.

   Not in our library10.1038/s41571-018-0113-0

7. 7.

   Reichardt LF. Neurotrophin-regulated signalling pathways. Phil Trans R Soc B2006; 361(1473): 1545–1564.

   Not in our library10.1098/rstb.2006.1894

8. 8.

   Cunningham ME, Greene LA. A function-structure model for NGF-activated TRK. EMBO J1998; 17(24): 7282–7293.

   Not in our library10.1093/emboj/17.24.7282

9. 9.

   Cohen S, Levi-Montalcini R, Hamburger V. A nerve growth-stimulating factor isolated from sarcomas 37 and 180. Proc Natl Acad Sci USA1954; 40(10): 1014–1018.

   Not in our library10.1073/pnas.40.10.1014

10. 10.

    Barbacid M. The Trk family of neurotrophin receptors. J Neurobiol1994; 25(11): 1386–1403.

    Not in our library10.1002/neu.480251107

11. 11.

    Kaplan DR, Hempstead BL, Martin-Zanca D et al The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science1991; 252(5005): 554–558.

    Not in our library10.1126/science.1850549

12. 12.

    Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature1991; 350(6314): 158–160.

    Not in our library10.1038/350158a0

13. 13.

    Klein R, Nanduri V, Jing SA et al The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell1991; 66(2): 395–403.

    Not in our library10.1016/0092-8674(91)90628-c

14. 14.

    Soppet D, Escandon E, Maragos J et al The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell1991; 65(5): 895–903.

    Not in our library10.1016/0092-8674(91)90396-g

15. 15.

    Squinto SP, Stitt TN, Aldrich TH et al trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell1991; 65(5): 885–893.

    Not in our library10.1016/0092-8674(91)90395-f

16. 16.

    Lamballe F, Klein R, Barbacid M. trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell1991; 66(5): 967–979.

    Not in our library10.1016/0092-8674(91)90442-2

17. 17.

    Ip NY, Stitt TN, Tapley P et al Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron1993; 10(2): 137–149.

    Not in our library10.1016/0896-6273(93)90306-c

18. 18.

    Cordon-Cardo C, Tapley P, Jing SQ et al The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell1991; 66(1): 173–183.

    Not in our library10.1016/0092-8674(91)90149-s

19. 19.

    Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem2003; 72: 609–642.

    Not in our library10.1146/annurev.biochem.72.121801.161629

20. 20.

    Clary DO, Reichardt LF. An alternatively spliced form of the nerve growth factor receptor TrkA confers an enhanced response to neurotrophin 3. Proc Natl Acad Sci USA1994; 91(23): 11133–11137.

    Not in our library10.1073/pnas.91.23.11133

21. 21.

    Strohmaier C, Carter BD, Urfer R et al A splice variant of the neurotrophin receptor trkB with increased specificity for brain-derived neurotrophic factor. EMBO J1996; 15(13): 3332–3337.

    Not in our library

22. 22.

    Eide FF, Vining ER, Eide BL et al Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci1996; 16(10): 3123–3129.

    Not in our library10.1523/jneurosci.16-10-03123.1996

23. 23.

    Guiton M, Gunn-Moore FJ, Glass DJ et al Naturally occurring tyrosine kinase inserts block high affinity binding of phospholipase C gamma and Shc to TrkC and neurotrophin-3 signaling. J Biol Chem1995; 270(35): 20384–20390.

    Not in our library10.1074/jbc.270.35.20384

24. 24.

    Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open2016; 1(2): e000023.

    Not in our library10.1136/esmoopen-2015-000023

25. 25.

    Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett2001; 169(2): 107–114.

    Not in our library10.1016/s0304-3835(01)00530-4

26. 26.

    Barbacid M, Lamballe F, Pulido D et al The trk family of tyrosine protein kinase receptors. Biochim Biophys Acta1991; 1072(2 − 3): 115–127.

    Not in our library10.1016/0304-419x(91)90010-i

27. 27.

    Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov2015; 5(1): 25–34.

    Not in our library10.1158/2159-8290.cd-14-0765

28. 28.

    Crowley C, Spencer SD, Nishimura MC et al Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell1994; 76(6): 1001–1011.

    Not in our library10.1016/0092-8674(94)90378-6

29. 29.

    Smeyne RJ, Klein R, Schnapp A et al Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature1994; 368(6468): 246–249.

    Not in our library10.1038/368246a0

30. 30.

    Farinas I, Yoshida CK, Backus C et al Lack of neurotrophin-3 results in death of spinal sensory neurons and premature differentiation of their precursors. Neuron1996; 17(6): 1065–1078.

    Not in our library10.1016/s0896-6273(00)80240-8

31. 31.

    Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci2001; 24: 677–736.

    Not in our library10.1146/annurev.neuro.24.1.677

32. 32.

    Chen KS, Nishimura MC, Armanini MP et al Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J Neurosci1997; 17(19): 7288–7296.

    Not in our library10.1523/jneurosci.17-19-07288.1997

33. 33.

    Kermani P, Hempstead B. Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med2007; 17(4): 140–143.

    Not in our library10.1016/j.tcm.2007.03.002

34. 34.

    Kermani P, Rafii D, Jin DK et al Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. J Clin Invest2005; 115(3): 653–663.

    Not in our library10.1172/jci200522655

35. 35.

    Dissen GA, Hill DF, Costa ME et al A role for trkA nerve growth factor receptors in mammalian ovulation. Endocrinology1996; 137(1): 198–209.

    Not in our library10.1210/endo.137.1.8536613

36. 36.

    Coppola V, Barrick CA, Southon EA et al Ablation of TrkA function in the immune system causes B cell abnormalities. Development2004; 131(20): 5185–5195.

    Not in our library10.1242/dev.01383

37. 37.

    Greco A, Villa R, Fusetti L et al The Gly571Arg mutation, associated with the autonomic and sensory disorder congenital insensitivity to pain with anhidrosis, causes the inactivation of the NTRK1/nerve growth factor receptor. J Cell Physiol2000; 182(1): 127–133.

    Not in our library10.1002/(sici)1097-4652(200001)182:1<127::aid-jcp14>3.0.co;2-0

38. 38.

    Indo Y, Tsuruta M, Hayashida Y et al Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet1996; 13(4): 485–488.

    Not in our library10.1038/ng0896-485

39. 39.

    Klein R, Smeyne RJ, Wurst W et al Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell1993; 75(1): 113–122.

    Not in our library

40. 40.

    Xu B, Goulding EH, Zang K et al Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci2003; 6(7): 736–742.

    Not in our library10.1038/nn1073

Cited by papers we hold 4

• Small molecule inhibitors targeting the cancers · 2022
  No notice
• Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial · 2022
  No notice
• Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma · 2021
  Not checked
• Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.